Acasti Pharma Inc.
ACST
$3.07
-$0.1199-3.76%
| Weiss Ratings | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.67 | |||
| Price History | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | -1.16% | |||
| 60-Day Total Return | 39.34% | |||
| 90-Day Total Return | 49.12% | |||
| Year to Date Total Return | 23.19% | |||
| 1-Year Total Return | 18.70% | |||
| 2-Year Total Return | -50.29% | |||
| 3-Year Total Return | -82.60% | |||
| 5-Year Total Return | -92.72% | |||
| 52-Week High % Change | -12.50% | |||
| 52-Week Low % Change | 95.35% | |||
| Price | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.84 | |||
| 52-Week Low Price | $1.72 | |||
| 52-Week Low Price (Date) | Sep 22, 2023 | |||
| 52-Week High Price (Date) | Jul 05, 2023 | |||
| Valuation | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 32.00M | |||
| Enterprise Value | 6.91M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.06 | |||
| Earnings Per Share Growth | 137.34% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.49 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.40 | |||
| Enterprise Value/EBITDA (TTM) | -0.53 | |||
| Enterprise Value/EBIT | -0.53 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 11.51M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 450-687-2262 | |||
| Address | 3009 boulevard de la Concorde East Laval, QC H7E 2B5 | |||
| Website | www.acastipharma.com | |||
| Country | Canada | |||
| Year Founded | 2002 | |||
| Profitability | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -7.93% | |||
| Return on Equity | -- | |||
| Income Statement | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -12.23M | |||
| EBIT (TTM) | -12.25M | |||
| Net Income (TTM) | -38.77M | |||
| Net Income Avl. to Common (TTM) | -38.77M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 38.52% | |||
| EPS Diluted (TTM) | -5.06 | |||
| EPS Diluted Growth (Q YOY) | 60.27% | |||
| Balance Sheet | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 25.11M | |||
| Cash Per Share (Q) | $2.18 | |||
| Total Current Assets (Q) | 26.88M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 64.68M | |||
| Current Ratio (Q) | 15.189 | |||
| Book Value Per Share (Q) | $6.88 | |||
| Total Assets (Q) | 76.19M | |||
| Total Current Liabilities (Q) | 1.77M | |||
| Total Debt (Q) | 24.00K | |||
| Total Liabilities (Q) | 11.51M | |||
| Total Common Equity (Q) | 64.68M | |||
| Cash Flow | ACST - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.45M | |||
| Cash from Financing (TTM) | 7.36M | |||
| Net Change in Cash (TTM) | -7.70M | |||
| Levered Free Cash Flow (TTM) | -7.85M | |||
| Cash from Operations (TTM) | -13.57M | |||
